Please email us at [email protected] with our item No, NDC#, UPC# or the product link if you have any quetions. We are located in Oceanside, California. Search over 110,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name. Please note, Prescription items can only be ordered by a Drug Manufacturer, Wholesaler, Hospital, Governmental Medical Facility, VA, Pharmacy, Physician, Physician Assistant, Nurse Practitioner, Dentist, Podiatrist, Optometrist, Veterinarian, Naturopath, Licensed Lab, Physical Therapist & Pharmacist in their scope of practice. No order will ship, unless you you have provided us the Medical License (and DEA Lic. in case of controlled drug) and we had verified that. Rx items can only be shipped to AZ, AR, CA, CT, DE, FL, GA, GU, HI, IL, KS, KY, LA, ME, MA, MI, NJ, NY, PA, PR, TX, TN, VA, WA, WI and WV. If you are an International Physician or Pharmacist, please contact us before ordering.


Rx Item-Zolgensma- Onasemnogene Abeparvovec-Xioi Susp For IV 8.3ml By Novartis

ZOLGENSMA- onasemnogene abeparvovec-xioi SUSP FOR IV 8.3ML By Novartis  NDC Code(s): 71894-110-01, 71894-115-01, 71894-120-02, 71894-121-03, view more
Packager: AveXis, Inc.
Category: HUMAN PRESCRIPZOLGENSMA- onasemnogene abeparvovec-xioi SUSP FOR IV 8.3ML By Novartis  NDC Code(s): 71894-110-01, 71894-115-01, 71894-120-02, 71894-121-03, view more
Packager: AveXis, Inc.
Category: HUMAN PRESCRIPZOLGENSMA- onasemnogene abeparvovec-xioi SUSP FOR IV 8.3ML By Novartis  NDC Code(s): 71894-110-01, 71894-115-01, 71894-120-02, 71894-121-03, view more
Packager: AveXis, Inc.
Category: HUMAN PRESCRIPItem No.:Rx71894-115-01 71894-115-01 NDC No.71894-115-01 71894-0115-01 71894011501 7189411501 UPC No.:371894115010 3-71894-11501-0 371894-115010 MPN 11001 Only Lic.-Physician, Pharmacy, Dentist, Drug Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.comVisit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.

Rx Item-Zolgensma- Onasemnogene Abeparvovec-Xioi Susp For IV 8.3ml By Novartis

$0.00

Item No.: Rx71894-115-01 71894-115-01 NDC No.71894-115-01 71894-0115-01 71894011501 7189411501 UPC No.:371894115010 3-71894-11501-0 371894-115010 MPN 11001 Only Lic.-Physician, Pharmacy, Dentist, Drug Mfg, Dist., Gov, Hospital, Lic.Lab, Naturalist, Naturopath, Np, Optometrist, Pharmacist, Pa, Physical Therapist, Podiatrist, Researchco., Uni., Va, Vet & Wholesalers In Scope Of Practice Can Order This Rx Item. Rx Item-Zolgensma- Onasemnogene Abeparvovec-Xioi Susp For IV 8.3ml By Novartis

Have a question?

  Out of stock, please email us with the item number or product link at [email protected] for the quantity available, current pricing and eligibility to purchase.

FDA Approves Zolgensma (onasemnogene abeparvovec-xioi) Gene Therapy to Treat Pediatric Patients with Spinal Muscular Atrophy

BOXED WARNING(WHAT IS THIS?)
WARNING: ACUTE SERIOUS LIVER INJURY

Acute serious liver injury and elevated aminotransferases can occur with ZOLGENSMA. ( 5.1)

Patients with pre-existing liver impairment may be at higher risk. ( 8.6)

Prior to infusion, assess liver function of all patients by clinical examination and laboratory testing (e.g., hepatic aminotransferases [aspartate aminotransferase (AST) and alanine aminotransferase (ALT)], total bilirubin, and prothrombin time). Administer systemic corticosteroid to all patients before and after ZOLGENSMA infusion. Continue to monitor liver function for at least 3 months after infusion ( 2.1) ( 2.3).
CLOSE
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use ZOLGENSMA safely and effectively. See full prescribing information for ZOLGENSMA.

ZOLGENSMA� (onasemnogene abeparvovec-xioi)
Suspension for intravenous infusion
Initial U.S. Approval: 2019
WARNING: ACUTE SERIOUS LIVER INJURY SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING.

Acute serious liver injury and elevated aminotransferases can occur with ZOLGENSMA. (5.1)

Patients with pre-existing liver impairment may be at higher risk. (8.6)

Prior to infusion, assess liver function of all patients by clinical examination and laboratory testing (e.g., hepatic aminotransferases [aspartate aminotransferase (AST) and alanine aminotransferase (ALT)], total bilirubin, and prothrombin time). Administer systemic corticosteroid to all patients before and after ZOLGENSMA infusion. Continue to monitor liver function for at least 3 months after infusion (2.1) (2.3).
INDICATIONS AND USAGE
ZOLGENSMA (onasemnogene abeparvovec-xioi) is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi‑allelic mutations in the survival motor neuron 1 (SMN1) gene. (1)

Limitation of Use:


The safety and effectiveness of repeat administration of ZOLGENSMA have not been evaluated. ( 1, 6.2)

The use of ZOLGENSMA in patients with advanced SMA (e.g., complete paralysis of limbs, permanent ventilator dependence) has not been evaluated. ( 1, 14)
DOSAGE AND ADMINISTRATION
ZOLGENSMA is for single-dose intravenous infusion only (2).


The recommended dosage of ZOLGENSMA is 1.1 � 10 14 vector genomes (vg) per kg of body weight.

Administer ZOLGENSMA as an intravenous infusion over 60 minutes. ( 2.1, 2.3)

Starting one day prior to ZOLGENSMA infusion, administer systemic corticosteroids equivalent to oral prednisolone at 1 mg/kg of body weight per day for a total of 30 days. At the end of the 30-day period of systemic corticosteroid treatment, check liver function by clinical examination and by laboratory testing. For patients with unremarkable findings, taper the corticosteroid dose over the next 28 days. If liver function abnormalities persist, continue systemic corticosteroids (equivalent to oral prednisolone at 1 mg/kg/day) until findings become unremarkable, and then taper the corticosteroid dose over the next 28 days. Consult expert(s) if patients do not respond adequately to the equivalent of 1 mg/kg/day oral prednisolone. ( 2.1)
DOSAGE FORMS AND STRENGTHS
ZOLGENSMA is a suspension for intravenous infusion, supplied as single‑use vials. (3)

ZOLGENSMA is provided in a kit containing 2 to 9 vials, as a combination of 2 vial fill volumes (either 5.5 mL or 8.3 mL). All vials have a nominal concentration of 2.0 � 1013 vector genomes (vg) per mL. Each vial of ZOLGENSMA contains an extractable volume of not less than either 5.5 mL or 8.3 mL. (3)

CONTRAINDICATIONS
None (4)

WARNINGS AND PRECAUTIONS

Thrombocytopenia: Monitor platelet counts before ZOLGENSMA infusion, and weekly for the first month and then every other week for the second and third month until platelet counts return to baseline. ( 2.3, 5.2)

Elevated Troponin‑I: Monitor troponin-I before ZOLGENSMA infusion, and weekly for the first month and then monthly for the second and third month until troponin-I level returns to baseline. ( 2.3, 5.3)
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥ 5%) were elevated aminotransferases and vomiting. (6)



To report SUSPECTED ADVERSE REACTIONS, contact AveXis at 1 833-828-3947 or FDA at 1-800-FDA-1088 or WWW.FDA.GOV/MEDWATCH.

USE IN SPECIFIC POPULATIONS
Pediatric use: Use of ZOLGENSMA in premature neonates before reaching full term gestational age is not recommended because concomitant treatment with corticosteroids may adversely affect neurological development. Delay ZOLGENSMA infusion until full-term gestational age is reached. (8.4)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 5/2019

ZOLGENSMA- onasemnogene abeparvovec-xioi SUSP FOR IV 8.3ML By Novartis  NDC Code(s): 71894-110-01, 71894-115-01, 71894-120-02, 71894-121-03, view more
Packager: AveXis, Inc.
Category: HUMAN PRESCRIP
ZOLGENSMA- onasemnogene abepar
ZOLGENSMA- onasemnogene abeparvovec-xioi SUSP FOR IV 8.3ML By Novartis NDC Code(s): 71894-110-01, 71894-115-01, 71894-120-02, 71894-121-03, view more Packager: AveXis, Inc. Category: HUMAN PRESCRIP

ZOLGENSMA- onasemnogene abeparvovec-xioi SUSP FOR IV 8.3ML By Novartis  NDC Code(s): 71894-110-01, 71894-115-01, 71894-120-02, 71894-121-03, view more
Packager: AveXis, Inc.
Category: HUMAN PRESCRIP
ZOLGENSMA- onasemnogene abepar
ZOLGENSMA- onasemnogene abeparvovec-xioi SUSP FOR IV 8.3ML By Novartis NDC Code(s): 71894-110-01, 71894-115-01, 71894-120-02, 71894-121-03, view more Packager: AveXis, Inc. Category: HUMAN PRESCRIP

ZOLGENSMA- onasemnogene abeparvovec-xioi SUSP FOR IV 8.3ML By Novartis  NDC Code(s): 71894-110-01, 71894-115-01, 71894-120-02, 71894-121-03, view more
Packager: AveXis, Inc.
Category: HUMAN PRESCRIP
ZOLGENSMA- onasemnogene abepar
ZOLGENSMA- onasemnogene abeparvovec-xioi SUSP FOR IV 8.3ML By Novartis NDC Code(s): 71894-110-01, 71894-115-01, 71894-120-02, 71894-121-03, view more Packager: AveXis, Inc. Category: HUMAN PRESCRIP

Item No.:Rx71894-115-01 71894-115-01 NDC No.71894-115-01 71894-0115-01 71894011501 7189411501 UPC No.:371894115010 3-71894-11501-0 371894-115010 MPN 11001 Only Lic.-Physician, Pharmacy, Dentist, Drug
ZOLGENSMA- onasemnogene abepar
Item No.:Rx71894-115-01 71894-115-01 NDC No.71894-115-01 71894-0115-01 71894011501 7189411501 UPC No.:371894115010 3-71894-11501-0 371894-115010 MPN 11001 Only Lic.-Physician, Pharmacy, Dentist, Drug

Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.com
Buy More Save More!
Want to do Research on this Med or need a large quantity? Email Details with quantity required to:[email protected]

Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.
AmericanPharmaWholesale.com
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.